The estimated Net Worth of Asit Parikh is at least $1.03 Million dollars as of 6 November 2023. Mr. Parikh owns over 7,500 units of Phathom Pharmaceuticals Inc stock worth over $1,028,500 and over the last 3 years he sold PHAT stock worth over $0. In addition, he makes $0 as Independent Director at Phathom Pharmaceuticals Inc.
Asit has made over 5 trades of the Phathom Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 7,500 units of PHAT stock worth $58,575 on 6 November 2023.
The largest trade he's ever made was buying 12,500 units of Phathom Pharmaceuticals Inc stock on 12 May 2022 worth over $100,000. On average, Asit trades about 2,818 units every 49 days since 2021. As of 6 November 2023 he still owns at least 55,000 units of Phathom Pharmaceuticals Inc stock.
You can see the complete history of Mr. Parikh stock trades at the bottom of the page.
Asit Parikh M.D. Ph.D. serves as Independent Director of the Company. Since October 2014, Dr. Parikh has served as the Senior Vice President and head of the Gastrointestinal Therapeutic Area Unit at Takeda Pharmaceuticals. Dr. Parikh has served in various positions at Takeda since 2006. Dr. Parikh received a bachelor’s degree in Biochemistry and Molecular Biology from Northwestern University and an M.D. and Ph.D. in Biochemistry and Molecular Biology from Vanderbilt University School of Medicine. He completed his internal medicine residency at the University of Pennsylvania and completed specialty training in gastroenterology at the Massachusetts General Hospital. He also completed postdoctoral work in cancer biology at Massachusetts Institute of Technology. Dr. Parikh’s extensive knowledge of our business and prior oversight of the Takeda team bringing vonoprazan to the Japanese market in seven indications contributed to our board of directors’ conclusion that he should serve as a director of our company.
Asit Parikh is 48, he's been the Independent Director of Phathom Pharmaceuticals Inc since 2019. There are 9 older and 4 younger executives at Phathom Pharmaceuticals Inc. The oldest executive at Phathom Pharmaceuticals Inc is Tadataka Yamada, 75, who is the Independent Chairman of the Board.
Asit's mailing address filed with the SEC is C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK, NJ, 07932.
Over the last 5 years, insiders at Phathom Pharmaceuticals Inc have traded over $112,538,769 worth of Phathom Pharmaceuticals Inc stock and bought 2,393,679 units worth $45,337,731 . The most active insiders traders include Capital Management, L.P.Ra ..., James N Topper und Pharmaceutical Co Ltd Takeda. On average, Phathom Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $2,226,815. The most recent stock trade was executed by Azmi Nabulsi on 15 July 2024, trading 10,901 units of PHAT stock currently worth $127,760.
phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.
Phathom Pharmaceuticals Inc executives and other stock owners filed with the SEC include: